What Is Reglan-Induced Tardive Dyskinesia?

From General Health Awareness to Targeted Risk Communication

If you've taken Reglan and noticed uncontrollable facial or limb movements, you may be experiencing tardive dyskinesia. This condition, rooted in the long-standing medical understanding of drug-induced movement disorders, requires careful evaluation. Here we explain what tardive dyskinesia is, why Reglan can cause it, and what you should know about diagnosis and monitoring.

Understanding Reglan and Tardive Dyskinesia: A Medical Overview

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent commonly prescribed for conditions such as diabetic gastroparesis and gastroesophageal reflux. However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. This section examines the clinical presentation, pharmacological mechanisms, and settlement-related considerations for affected patients, based on provided evidence. Tardive dyskinesia is a syndrome characterized by involuntary, repetitive movements, often involving the face, tongue, trunk, or extremities. According to the FDA-approved labeling, TD can manifest as 'potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition may be partially suppressed by metoclopramide itself, potentially delaying diagnosis because the drug can 'mask the underlying disease process' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Diagnosis typically involves clinical observation of abnormal movements after exposure to a dopamine receptor blocking agent, with differentiation from other extrapyramidal symptoms. A case report highlights that TD can occur even after a single dose of metoclopramide, as seen in a postoperative gynecological patient who developed dyskinetic movements after intraoperative administration (https://pubmed.ncbi.nlm.nih.gov/34712535/). This underscores the importance of recognizing risk factors, such as pre-existing neurological conditions or concomitant use of other dopamine-blocking drugs.

Pharmacology and Reported Adverse Effects of Reglan

Metoclopramide acts as a dopamine D2-receptor antagonist, which is central to its therapeutic effects in treating nausea and gastroparesis. However, this mechanism also leads to extrapyramidal side effects, including TD. The FDA boxed warning states that 'metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk increases with longer treatment duration and higher cumulative dosage. For patients with diabetic gastroparesis, the labeling advises avoiding treatment beyond 12 weeks, and if longer use is unavoidable, routine monitoring for TD signs is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Similarly, for symptomatic gastroesophageal reflux, the maximum treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling also warns against concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome, and advises immediate discontinuation if symptoms occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanistic Pathways Linking Reglan to Tardive Dyskinesia

The primary mechanism involves chronic blockade of dopamine D2 receptors in the striatum, leading to supersensitivity of these receptors and subsequent hyperkinetic movements. This is supported by the fact that VMAT2 inhibitors, which modulate dopamine storage and release, are used to treat TD (https://pubmed.ncbi.nlm.nih.gov/29433808/). The risk is not limited to antipsychotics; antiemetics like metoclopramide carry a similar incidence of TD (https://pubmed.ncbi.nlm.nih.gov/29433808/). The case report of TD after a single dose suggests that individual susceptibility, such as genetic factors or prior neurological conditions, may play a role (https://pubmed.ncbi.nlm.nih.gov/34712535/). The FDA labeling emphasizes that TD can be 'potentially irreversible,' highlighting the seriousness of this adverse effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Adequacy of Warnings and Settlement Considerations

The FDA has mandated a boxed warning for Reglan, which is the strongest safety warning. The warning clearly states the risk of TD, its potential irreversibility, and the need for short-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). It also contraindicates Reglan in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, cases of TD continue to occur, possibly due to inadequate patient monitoring or off-label long-term use. The labeling advises periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the adequacy of warnings in clinical practice may be questioned if patients are not fully informed of the risks or if prescribers do not adhere to duration limits. Patients who develop TD after Reglan use may pursue legal claims based on inadequate warnings or failure to monitor. Settlement criteria often consider the severity of TD, duration of Reglan use, and whether the patient was warned of the risk. The FDA boxed warning provides a strong basis for claims, as it establishes that the manufacturer knew of the risk. However, settlements may be influenced by factors such as the patient's adherence to prescribed duration and the presence of other risk factors. The case report of TD after a single dose suggests that even short-term use can lead to harm, potentially strengthening claims for patients with minimal exposure (https://pubmed.ncbi.nlm.nih.gov/34712535/). Additionally, the availability of VMAT2 inhibitors for treatment may affect settlement amounts, as these drugs can manage symptoms but not reverse TD (https://pubmed.ncbi.nlm.nih.gov/29433808/). The onset of TD can vary widely. While the risk increases with longer treatment, cases have been reported after a single dose, as in the postoperative patient (https://pubmed.ncbi.nlm.nih.gov/34712535/). The FDA labeling notes that TD may be suppressed or partially suppressed by metoclopramide, potentially delaying diagnosis until after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This delay complicates the establishment of a causal timeline. For settlement purposes, documentation of the exposure period and the onset of symptoms is critical. The labeling's recommendation for immediate discontinuation upon symptom development underscores the need for prompt recognition (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Request a Free Case Review